### CEVEC Pharmaceuticals GmbH

**Field of Activity**
Development, services and licensing of cell-based production platforms for biopharmaceuticals.

**Ownership Structure and Financing**
Privately owned; main investors are Peppermint Venture Partners, Creatior Venture, NRW.Bank, KiW Bank, G.A.T. Holding and Investtostate GmbH

**Partners**
Selected license partners: Beckman Research Institute, Biolamina AB, Biostest AG, CellGenix GmbH, CSL Limited, Genethon, medac, FlaimidFactory GmbH & Co. KG and Provecs Medical GmbH

**CDMO partners:** Paragon Bioservices Inc. and Genbet Biopharmaceuticals

**Technology and Unique Selling Point**
CEVEC’s human suspension cell-based CAP technology provides fully scalable, clinical-grade good manufacturing practice (GMP) compatible solutions for the production of viral gene therapy vectors and recombinant glycoproteins. The CAP-GT platform includes a helper-free AAV packaging cell line for stable vector production and RCA-free production of adenoviral vectors for gene therapy applications. The CAP-Go system provides outstanding pharmacokinetic profiles and characteristics in terms of authentic and tailor-made glycosylation capabilities as well as high yield production of complex proteins.

**Products/Services**
Cell line and process development and technology licensing for the production of tailor-made recombinant glycoproteins and gene therapy vectors.

**Membership in Networks/Associations**
BioRiver, Bio Cologne, Bio Deutschland, Dechema, VCI

---

### Secarna Pharmaceuticals GmbH & Co. KG

**Field of Activity**
Discovering, testing and selecting ASOs of the third generation for pre-clinical and clinical development in a variety of therapeutic indications.

**Partners**
Secarna’s objective is to form strategic partnerships leveraging the strengths of the Company and its partners to produce maximum value for the benefit of the alliances throughout their lifetimes. Secarna’s LNAplus™ platform and ASOs have been validated by in-house projects as well as in academic and industry collaborations.

**Unique Selling Point**
Secarna’s proprietary, customized, in-house drug discovery platform LNAplus™ encompasses all aspects of drug discovery and pre-clinical development, including a powerful proprietary bioinformatics modelling system, a best-in-class high throughput screening system, and bespoke target-specific functional assays. This results in highly specific, safe and efficacious antisense therapies for challenging or currently not druggable targets.

---

### Address

**Address**
Gottfried-Hagen-Straße 60-62
51105 Cologne

**Telephone/Telefax**
+49 221 460 208-00/-01

**E-mail**
info@cevec.com

**Web Address**
www.cevec.com

**Date of Incorporation/Number of Employees**
2003/30 employees

---

**Address**
Am Klopferspitz 19
82152 Planegg/Martinsried

**Telephone/Telefax**
+49 89 215 46 375 / +49 6421 98300599

**E-mail**
info@secarna.com

**Web Address**
www.secarna.com

**Date of Incorporation/Number of Employees**
2015/15

---

Jonas Renz, Managing Director & Co-Founder